• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail
-
-

2010 Warning Letters

Recently Posted | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996

Warning Letters issued in 2010

 

* Not issued: A close-out letter may issue when, based on FDA’s evaluation, the firm has taken corrective action to address the violations contained in the Warning Letter. This procedure applies to Warning Letters issued on or after September 1, 2009.

* N/A: Not applicable, the Warning Letter was issued prior to September 1, 2009.

Read more about warning and close-out letters

Posted on February 23, 2010

Letter Issue Date Company Name Issuing Office Subject Close Out Date
February 12, 2010 LCA Vision Inc/Lasik Plus Vision Center Center for Devices and Radiological Health Medical Device Reporting Regulation/Misbranded August 16, 2011
February 12, 2010 Lasik Vision Institute Center for Devices and Radiological Health Medical Device Reporting Regulation/Misbranded Not Issued *
February 11, 2010 Rangen Inc Seattle District Office Animal Proteins Prohibited in Ruminant Feed/Adulterated/Misbranded Not Issued *
February 09, 2010 Lomeo, Simon J. New York District Office Illegal Drug Residue Not Issued *
February 09, 2010 Breckenridge Pharmaceutical, Inc. Florida District Office New Drug/Adulterated Not Issued *
February 09, 2010 P & D Dairy Los Angeles District Office Illegal Drug Residue Not Issued *
February 08, 2010 Poly Pharmaceuticals, Inc New Orleans District Office New Drug/Adulterated Not Issued *
February 08, 2010 Magna Pharmaceuticals, Inc Cincinnati District Office Labeling/False & Misleading Claims/New Drug/Misbranded Not Issued *
February 08, 2010 Jaymac Pharmaceuticals LLC New Orleans District Office New Drug/Adulterated Not Issued *
February 08, 2010 Edwards Pharmaceuticals, Inc New Orleans District Office New Drug/Adulterated Not Issued *


 

Contact FDA

301-796-8490
FDA's Office of Critical Path Programs
-
-
-